Strategic Cooperation Signed Between Zybio And Beckman Coulter
Nov 05, 2025 Zybio News
-

Oct 31, 2025
DiagHub Online Academic Platform The seventh session on Coagulation Concludes Successfully – Highlights Recap
-

September 26, 2025
DiagHub Online Academic Platform The sixth session on Hematology Concludes Successfully – Highlights Recap
-

August 29, 2025
DiagHub Online Academic Platform The fifth session on Microbiology Concludes Successfully – Highlights Recap
On October 31, 2025, Zybio Inc. and Beckman Coulter Commercial Enterprise (China) Co., Ltd officially signed a strategic cooperation agreement on the site of NCLM exhibition in China.
Strategic Alignment Outlines a New Blueprint for Collaboration
During the speech segment of the ceremony, representatives from both sides elaborated on the strategic value and future vision of this partnership.

Mr. Wenhao Sun, Director and General Manager of the Domestic Marketing Department at Zybio, expressed that Zybio looks forward to both sides integrating technological expertise and innovation advantages to drive the deep integration of medical diagnostic technologies and bring new vitality to China's laboratory medicine.

Mr. Huai Chen, Global Vice President of Beckman Coulter Diagnostics and General Manager in China, emphasized that Beckman Coulter Diagnostics consistently upholds a long-term approach and is steadfastly advancing its localization strategy of improvement with innovation in China. He noted that with Zybio, a key member of their local cooperation ecosystem, both sides are expected to combine the strengths and resources to create value and jointly explore new patterns and extend frontiers in medical testing, ultimately bringing benefits to the public.
Inking the Agreement, Opening a New Chapter of Win-Win Collaboration
Witnessed by Ms. Jingyun Liu, General Manager of Zybio's Medical Market Center and Director of the General Administration Office, Mr. Hui Yan, Sales Director of Beckman Coulter's EAS & HAI division, and all guests present, representatives from both sides solemnly signed the agreement, marking the official beginning of a new collaborative journey.

This strategic partnership between Zybio and Beckman Coulter is not merely a commercial collaboration but also a synergistic advancement within the industry, guided by the "Healthy China" strategy. Both sides, with this signing ceremony as a starting point, will jointly inject new vitality into the high-quality development of China's laboratory medicine and contribute to safeguarding health worldwide.